Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease

American Journal of Medicine

Volumn 125, Issue 4, 2012, Pages 399-410

  Ahmed, Ali ^a,b   Fonarow, Gregg C ^c   Zhang, Yan ^a   Sanders, Paul W ^a,b   Allman, Richard M ^a,b   Arnett, Donna K ^a   Feller, Margaret A ^d   Love, Thomas E ^d   Aban, Inmaculada B ^a   Levesque, Raynald ^e   Ekundayo, O James ^c,f   Dell'Italia, Louis J ^a,b   Bakris, George L ^g   Rich, Michael W ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e Meharry Medical College ^*

^f MEHARRY MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h WASHINGTON UNIVERSITY   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Systolic heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FUNCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HEART FAILURE;

AGED; AGED, 80 AND OVER; ALABAMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84862778264     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.10.013     Document Type: Article

References (47)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-479.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
3. Ahmed A, Rich MW, Sanders PW, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007;99:393-398.
4. Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008;4:387-399.
5. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354: 131-140. (Pubitemid 43076710)
6. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003; 289:305-312. (Pubitemid 36083983)
7. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 1997;79:1118-1120. (Pubitemid 27217073)
8. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685-693. (Pubitemid 30140419)
9. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc. 2002;50:1297-1300. (Pubitemid 34774558)
10. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
11. Rubin DB. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169-188.
12. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA. 2002;287:3130-3132. (Pubitemid 34633989)
13. Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32:1704-1708.
14. Feller MA, Mujib M, Zhang Y, et al. Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: Findings from the Alabama Heart Failure Project. Int J Cardiol. 2011 May 26. [Epub ahead of print] doi:10.1016/j.ijcard.2011.05.003.
15. Zhang Y, Fonarow GC, Sanders PW, et al. A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥65 years. Am J Cardiol. 2011;108:1443-1448.
16. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
17. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
18. Heywood JT, Fonarow GC, Yancy CW, et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail. 2010;3:596-605.
19. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-1439. (Pubitemid 43998077)
20. Mujib M, Desai RV, Ahmed MI, et al. Rheumatic heart disease and risk of incident heart failure among community-dwelling older adults: a prospective cohort study. Ann Med. 2011 Jan 24. [Epub ahead of print] doi:10.3109/07853890. 2010.530685.
21. Mujib M, Rahman AA, Desai RV, et al. Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. Am J Cardiol. 2011;107:552-557.
22. Ahmed MI, Lainscak M, Mujib M, et al. Gender-related dissociation in outcomes in chronic heart failure: reduced mortality but similar hospitalization in women. Int J Cardiol. 2011;148:36-42.
23. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208-1214.
24. Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32:712-720.
25. Gheorghiade M, Flaherty JD, Fonarow GC, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol. 2011;151:69-75.
26. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1: 62-67.
27. Ekundayo OJ, Dell'Italia LJ, Sanders PW, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010;142:279-287.
28. Giamouzis G, Agha SA, Ekundayo OJ, et al. Incident coronary revascularization and subsequent mortality in chronic heart failure: a propensity-matched study. Int J Cardiol. 2010;140:55-59.
29. Iyer AS, Ahmed MI, Filippatos GS, et al. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010;4:22-31.
30. Garg R, Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
31. Cohn JN. Physiologic basis of vasodilator therapy for heart failure. Am J Med. 1981;71:135-139. (Pubitemid 12254722)
32. Pfeffer JM, Pfeffer MA. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med. 1988;84:37-44.
33. Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med. 2006;354:189-191. (Pubitemid 43076717)
34. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980;302: 1373-1379.
35. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186. (Pubitemid 40091809)
36. Gheorghiade M, Bonow RO. Introduction and overview: beta-blocker therapy in the management of chronic heart failure. Am J Med. 2001; 110(Suppl 7A):1S-5S.
37. Carson P, Anand I, O'Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2329-2334. (Pubitemid 41785506)
38. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-1592. (Pubitemid 39369790)
39. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160:2645-2650.
40. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002;50:1659-1666. (Pubitemid 35192537)
41. Ahmed A, Centor R, Weaver MT, DeLong JF. A propensity score analysis of the impact of ACE inhibitors on 4-year survival of older adults with heart failure and perceived contraindications. Am Heart J. 2005;149:737-743.
42. Ahmed A, Love TE, Sui X, Rich MW. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. J Card Fail. 2006;12:499-506. (Pubitemid 44335822)
43. Bowling CB, Pitt B, Ahmed MI, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3:253-260.
44. Ahmed MI, Ekundayo OJ, Mujib M, et al. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010;144:383-388.
45. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004;43:2036-2043. (Pubitemid 38686798)
46. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341-353. (Pubitemid 29383482)
47. Mujib M, Zhang Y, Feller MA, Ahmed A. Evidence of a "heart failure belt" in the southeastern United States. Am J Cardiol. 2011;107:935-937.